Menu Search
Equities

Abionyx Pharma SA

609:BER

Abionyx Pharma SA

Actions
  • Price (EUR)1.29
  • Today's Change0.008 / 0.62%
  • Shares traded0.00
  • 1 Year change+16.22%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:15 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Abionyx Pharma SA had revenues fall -11.65% from 5.25m to 4.64m, though the company grew net income from a loss of 4.21m to a smaller loss of 3.52m.
Gross margin19.19%
Net profit margin-69.15%
Operating margin-68.12%
Return on assets-22.93%
Return on equity-47.16%
Return on investment-33.15%
More ▼

Cash flow in EURView more

In 2023, Abionyx Pharma SA did not generate a significant amount of cash. Cash Flow from Financing totalled 3.89m or 83.75% of revenues. In addition the company used 3.70m for operations while cash used for investing totalled 130.00k.
Cash flow per share-0.1022
Price/Cash flow per share--
Book value per share0.2934
Tangible book value per share0.124
More ▼

Balance sheet in EURView more

Abionyx Pharma SA has a Debt to Total Capital ratio of 25.13%, a lower figure than the previous year's 61.13%.
Current ratio2.28
Quick ratio2.22
Total debt/total equity0.3356
Total debt/total capital0.2513
More ▼

Growth rates in EUR

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		23.12
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.